NF1 and breast carcinoma: NF1 loss-of-function mutations are detectable in about 2% of primary ER+ breast tumors (8), but up to 20% of the primary ER+ breast cancer can be considered NF1-deficient because of an association with a poor response to adjuvant endocrine therapy at the mRNA level (9).